PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Insilico Medicine raises $60m in Series D round

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.

The financing comprised a mix of new investors, including a large, diversified asset management firm on the US West Coast and BHR Partners, along with current investors, including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. 

Insilico’s founder and CEO, Alex Zhavoronkov, PhD, also invested in the Series D round.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured